Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PBA-0405
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Pure Biologics
Deal Size : Not Applicable
Deal Type : Not Applicable
Presage Announces FDA Study May Proceed to Evaluate Pre-GMP Candidate in Phase 0 Trial
Details : PBA-0405 is a novel ROR1 Inhibitor antibody with significantly improved therapeutic properties, which is currently being evaluated for the treatment of cancer.
Brand Name : PBA-0405
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 16, 2024
Lead Product(s) : PBA-0405
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Pure Biologics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Labcorp
Deal Size : $13.0 million
Deal Type : Financing
Details : The proceeds from this financing will support expansion of Presage's existing network of clinical sites in the U.S. and Australia, as well as development of next-generation CIVO microdose injection devices designed to access a wider spectrum of cancers.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 02, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Labcorp
Deal Size : $13.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?